Published in Mol Ther on October 04, 2011
Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol (2013) 2.81
Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol (2014) 2.75
Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol (2013) 1.97
Progress toward in vivo use of siRNAs-II. Mol Ther (2011) 1.60
Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells. Mol Ther Nucleic Acids (2012) 1.24
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Mol Ther Nucleic Acids (2012) 1.16
Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model. Proc Natl Acad Sci U S A (2012) 0.94
Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain. Mol Ther Nucleic Acids (2013) 0.92
Neutral polymeric micelles for RNA delivery. Bioconjug Chem (2013) 0.86
PEGylated cationic liposome-DNA complexation in brine is pathway-dependent. Biochim Biophys Acta (2013) 0.83
Delivery of siRNAs to Dendritic Cells Using DEC205-Targeted Lipid Nanoparticles to Inhibit Immune Responses. Mol Ther (2015) 0.80
Next generation delivery system for proteins and genes of therapeutic purpose: why and how? Biomed Res Int (2014) 0.79
Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery. J Histochem Cytochem (2013) 0.79
Minocycline hydrochloride nanoliposomes inhibit the production of TNF-α in LPS-stimulated macrophages. Int J Nanomedicine (2012) 0.78
Identification of siRNA delivery enhancers by a chemical library screen. Nucleic Acids Res (2015) 0.78
Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol Ther (2017) 0.77
The Niemann-Pick C1 Inhibitor NP3.47 Enhances Gene Silencing Potency of Lipid Nanoparticles Containing siRNA. Mol Ther (2016) 0.77
Targeting DNA vaccines to myeloid cells using a small peptide. Eur J Immunol (2014) 0.76
Influence of cationic lipid concentration on properties of lipid-polymer hybrid nanospheres for gene delivery. Int J Nanomedicine (2015) 0.76
Differential bioreactivity of neutral, cationic and anionic polystyrene nanoparticles with cells from the human alveolar compartment: robust response of alveolar type 1 epithelial cells. Part Fibre Toxicol (2015) 0.75
Nanostructured lipid carriers loaded with resveratrol modulate human dendritic cells. Int J Nanomedicine (2016) 0.75
Autonomously folded α-helical lockers promote RNAi. Sci Rep (2016) 0.75
Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo. Mol Ther Nucleic Acids (2016) 0.75
Non-viral nanoparticle delivers small interfering RNA to macrophages in vitro and in vivo. PLoS One (2015) 0.75
Mathematical Modeling: A Tool for Optimization of Lipid Nanoparticle-Mediated Delivery of siRNA. Mol Ther Nucleic Acids (2017) 0.75
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A (1987) 18.91
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol (2008) 6.81
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 5.37
RNA interference in adult mice. Nature (2002) 5.33
Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97
Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science (2008) 3.51
LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol (1994) 3.47
Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. Proc Natl Acad Sci U S A (1989) 3.28
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther (2010) 3.26
Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature (2009) 3.21
RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev (2007) 3.13
Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet (2002) 3.08
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc Natl Acad Sci U S A (1996) 2.65
Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A (2003) 2.34
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 2.19
Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther (2008) 2.02
Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta (2001) 1.78
A model for non-viral gene delivery: through syndecan adhesion molecules and powered by actin. J Gene Med (2004) 1.65
Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J (2001) 1.64
Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm (2002) 1.58
Phagocytosis: latex leads the way. Curr Opin Cell Biol (2003) 1.54
The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther (2008) 1.41
Stabilized plasmid-lipid particles: construction and characterization. Gene Ther (1999) 1.33
Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther (2004) 1.23
Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J Biol Chem (1998) 1.21
Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. Hum Gene Ther (1992) 1.15
CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J Neurosci (2000) 1.14
Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol (2003) 1.11
Tunable pH-sensitive liposomes composed of mixtures of cationic and anionic lipids. Biophys J (2000) 1.11
Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta (1996) 1.10
Cationic liposome-mediated intravenous gene delivery. J Biol Chem (1995) 1.05
A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood (2009) 1.04
Influence of dose on liposome clearance: critical role of blood proteins. Biochim Biophys Acta (1996) 0.98
Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature (1996) 0.97
Immunotoxicity of monoclonal antibodies. MAbs (2009) 0.97
Antibody-mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy. Proc Natl Acad Sci U S A (1998) 0.94
Uptake of liposomes containing phosphatidylserine by liver cells in vivo and by sinusoidal liver cells in primary culture: in vivo-in vitro differences. Biochem Biophys Res Commun (1999) 0.93
Nature of linkage between the cationic headgroup and cholesteryl skeleton controls gene transfection efficiency. FEBS Lett (2000) 0.89
The immunostimulatory activity of unmethylated and methylated CpG oligodeoxynucleotide is dependent on their ability to colocalize with TLR9 in late endosomes. J Immunol (2010) 0.88
Analytical methods for the characterization of cationic lipid-nucleic acid complexes. Hum Gene Ther (1998) 0.87
Uptake of phosphatidylserine-containing liposomes by liver sinusoidal endothelial cells in the serum-free perfused rat liver. Biochim Biophys Acta (2005) 0.84
Effects of RNA interference on CD80 and CD86 expression in bone marrow-derived murine dendritic cells. Scand J Immunol (2006) 0.83
Prevention of allograft rejection by in vitro generated tolerogenic dendritic cells. Transpl Immunol (2003) 0.82
The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Biochim Biophys Acta (1993) 0.82
Target specific optimization of cationic lipid-based systems for pulmonary gene therapy. Pharm Res (1998) 0.80
Adverse effects of immunotherapeutics involving the immune system. Toxicology (2002) 0.79
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature (2010) 12.07
Drug delivery systems: entering the mainstream. Science (2004) 9.27
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol (2008) 6.81
Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57
Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev (2012) 4.30
Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A (2010) 4.25
Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol (2011) 3.95
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther (2010) 3.26
Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol (2013) 2.81
Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A (2012) 2.42
Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther (2009) 2.39
Molecular architecture and functional model of the complete yeast ESCRT-I heterotetramer. Cell (2007) 2.21
Loss of NFAT5 results in renal atrophy and lack of tonicity-responsive gene expression. Proc Natl Acad Sci U S A (2004) 2.12
Interaction landscape of membrane-protein complexes in Saccharomyces cerevisiae. Nature (2012) 2.05
Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J Immunol (2006) 1.93
Structure/property studies of polymeric gene delivery using a library of poly(beta-amino esters). Mol Ther (2005) 1.87
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl (2012) 1.87
Rab5 is necessary for the biogenesis of the endolysosomal system in vivo. Nature (2012) 1.82
A polymer library approach to suicide gene therapy for cancer. Proc Natl Acad Sci U S A (2004) 1.79
Imaging transcription in living cells. Annu Rev Biophys (2009) 1.76
Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. J Biol Chem (2012) 1.75
Allelic 'choice' governs somatic hypermutation in vivo at the immunoglobulin kappa-chain locus. Nat Immunol (2007) 1.68
Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature (2007) 1.66
Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood (2012) 1.64
Heme oxygenase-1 is an anti-inflammatory host factor that promotes murine plasmodium liver infection. Cell Host Microbe (2008) 1.62
The liposomal formulation of doxorubicin. Methods Enzymol (2005) 1.62
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One (2009) 1.55
Host scavenger receptor SR-BI plays a dual role in the establishment of malaria parasite liver infection. Cell Host Microbe (2008) 1.50
Quantitative mass spectrometry reveals a role for the GTPase Rho1p in actin organization on the peroxisome membrane. J Cell Biol (2004) 1.38
Gene silencing activity of siRNAs with a ribo-difluorotoluyl nucleotide. ACS Chem Biol (2006) 1.33
Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc (2014) 1.31
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Natl Acad Sci U S A (2014) 1.30
Inp1p is a peroxisomal membrane protein required for peroxisome inheritance in Saccharomyces cerevisiae. J Cell Biol (2005) 1.29
Liposomal nanomedicines. Expert Opin Drug Deliv (2008) 1.26
Notch ligand delta-like 4 blockade attenuates atherosclerosis and metabolic disorders. Proc Natl Acad Sci U S A (2012) 1.26
Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. Immunity (2002) 1.25
Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells. Mol Ther Nucleic Acids (2012) 1.24
Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther (2004) 1.23
Antibody repertoires generated by VH replacement and direct VH to JH joining. Immunity (2006) 1.21
Unique gene-silencing and structural properties of 2'-fluoro-modified siRNAs. Angew Chem Int Ed Engl (2011) 1.20
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Mol Ther Nucleic Acids (2012) 1.16
Identification of neuropeptide W as the endogenous ligand for orphan G-protein-coupled receptors GPR7 and GPR8. J Biol Chem (2002) 1.13
Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. Langmuir (2012) 1.13
Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release (2005) 1.12
Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery. Bioconjug Chem (2010) 1.11
Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther (2013) 1.11
Delivering silence: advancements in developing siRNA therapeutics. Curr Opin Drug Discov Devel (2008) 1.10
Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. Adv Drug Deliv Rev (2009) 1.09
Cytokines in the generation and maturation of dendritic cells: recent advances. Eur Cytokine Netw (2002) 1.08
Direct in vivo VH to JH rearrangement violating the 12/23 rule. J Exp Med (2005) 1.05
YHR150w and YDR479c encode peroxisomal integral membrane proteins involved in the regulation of peroxisome number, size, and distribution in Saccharomyces cerevisiae. J Cell Biol (2003) 1.04
Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta (2006) 1.04
Extrusion technique to generate liposomes of defined size. Methods Enzymol (2003) 1.03
Expression of a targeted lambda 1 light chain gene is developmentally regulated and independent of Ig kappa rearrangements. J Exp Med (2003) 1.02
Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother (2012) 1.01
Liposomal nanomedicines: an emerging field. Toxicol Pathol (2008) 1.01
Expression and functional importance of collagen-binding integrins, alpha 1 beta 1 and alpha 2 beta 1, on virus-activated T cells. J Immunol (2003) 0.98
Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo. RNA (2012) 0.98
Highly effective gene transfection in vivo by alkylated polyethylenimine. J Drug Deliv (2011) 0.96
In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR). Silence (2010) 0.96
Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core. J Phys Chem C Nanomater Interfaces (2012) 0.93
Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood (2006) 0.93
Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain. Mol Ther Nucleic Acids (2013) 0.92
Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci (2005) 0.92
Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung. J Thorac Oncol (2009) 0.91
Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J Control Release (2005) 0.91
Assessing siRNA pharmacodynamics in a luciferase-expressing mouse. Mol Ther (2008) 0.91
Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta (2007) 0.90
Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int J Cancer (2012) 0.90
Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. Int Immunol (2009) 0.90
CSF transthyretin neuroprotection in a mouse model of brain ischemia. J Neurochem (2010) 0.90